

Fasiglifam

Catalog No: tcsc0282



Available Sizes

Size: 2mg

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg



Specifications

CAS No:

1000413-72-8

Formula:

$C_{29}H_{32}O_7S$

Pathway:

GPCR/G Protein

Target:

GPR40

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 128 mg/mL (243.98 mM)

Alternative Names:

TAK-875

Observed Molecular Weight:

524.63


Product Description

Fasiglifam (TAK-875) is a potent, selective and orally bioavailable **GPR40** agonist with **EC₅₀** of 72 nM.

IC50 & Target: EC50: 72 nM (GPR40)

In Vitro: Fasiglifam (TAK-875) (0.01-10 μ M) produces a concentration-dependent increase in intracellular IP production in CHO-hGPR40, with EC₅₀ of 0.072 μ M. Fasiglifam (TAK-875) (0.1-10 μ M) dose-dependently augments intracellular IP production in CHO cells [1]. Fasiglifam (TAK-875) (3-30 μ M) concentration-dependently augments [Ca²⁺]_i. In the presence of 10 mM glucose, TAK-875 (0.001-10 μ M) dose-dependently stimulates insulin secretion from INS-1 833/15 cells [2].

In Vivo: Fasiglifam (TAK-875) (10 mg/kg, p.o.) increases plasma insulin levels in ZDF rats. Fasiglifam (TAK-875) (30 mg/kg, p.o.) improves fasting hyperglycemia without affecting fasting normoglycemia. Fasiglifam (TAK-875) at 30 mg/kg, which is a 3- to 10-fold higher dose compared with the dose that improved glucose tolerance in diabetic rats, does not alter fasting glucose levels in SD rats with normal glucose homeostasis. Likewise, Fasiglifam (TAK-875) does not significantly alter insulin secretion in SD rats with normal fasting glucose levels [1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!